Market Spotlight: Myelofibrosis (MF)
Market Spotlight: Myelofibrosis (MF)
$1,318.00
This Market Spotlight report covers the Myelofibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
Myelofibrosis is a myeloproliferative neoplasm which can exist as a primary disease known as primary myelofibrosis, or can evolve to post-polycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis from PV or ET. It is characterized by the buildup of scar tissue (fibrosis) in bone marrow, which leads to a reduction in blood cell production.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
- Bristol Myers Squibb’s Inrebic and Incyte’s Jakafi are the only marketed drugs for myelofibrosis. These drugs are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II, with one drug in the NDA/BLA stage.
- Therapies in development for myelofibrosis focus on a wide variety of targets. The majority of the pipeline drugs are administered via the oral route.
- High-impact upcoming events for drugs in the myelofibrosis space comprise topline Phase III trial results for pacritinib, Reblozyl, momelotinib, and imetelstat.
- The overall likelihood of approval of a Phase I hematologic asset is 9.2%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for myelofibrosis have been in the early and mid-phases of development, with 83% of trials in Phase I–II, and only 17% in Phase III–IV.
- The US has a substantial lead in the number of myelofibrosis clinical trials globally. Germany leads the major European markets, while Israel has the top spot in Asia.
- Novartis has the highest number of completed clinical trials for myelofibrosis, with 15 trials.
- Novartis leads industry sponsors with the highest overall number of clinical trials for myelofibrosis, followed by Incyte
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Anemia
9 Splenomegaly
10 Curative treatment
12 EPIDEMIOLOGY
14 MARKETED DRUGS
16 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 Bomedemstat for Myelofibrosis (December 5, 2020)
24 Momelotinib for Myelofibrosis (December 5, 2020)
25 Pelabresib for Myelofibrosis (December 5, 2020)
26 Momelotinib for Myelofibrosis (May 6, 2020)
27 Navitoclax for Myelofibrosis (December 9, 2019)
28 Reblozyl for Myelofibrosis (November 6, 2019)
30 Pracinostat for Myelofibrosis (July 31, 2019)
32 KEY UPCOMING EVENTS
33 KEY REGULATORY EVENTS
33 EU Approvals Beckon For Inrebic & Novel Adalimumab Biosimilar
33 CTI’s Pacritinib Rolls Toward A Return
33 Winners & Losers: A Deep-Dive Into The EMA’s PRIME Scheme
34 PROBABILITY OF SUCCESS
35 LICENSING AND ASSET ACQUISITION DEALS
35 Bristol Acquisition Of Forbius Driven By TGF-beta Assets
36 REVENUE OPPORTUNITY
37 CLINICAL TRIAL LANDSCAPE
38 Sponsors by status
39 Sponsors by phase
41 BIBLIOGRAPHY
41 Prescription information
42 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of myelofibrosis, 2019–28
16 Figure 2: Overview of pipeline drugs for myelofibrosis in the US
16 Figure 3: Pipeline drugs for myelofibrosis, by company
17 Figure 4: Pipeline drugs for myelofibrosis, by drug type
17 Figure 5: Pipeline drugs for myelofibrosis, by classification
27 Figure 6: Momelotinib for Myelofibrosis (May 6, 2020): Phase III – Simplify 2 (vs Best Available Therapy)
30 Figure 7: Reblozyl for Myelofibrosis (November 6, 2019): Phase II – MF-001
32 Figure 8: Key upcoming events in myelofibrosis
34 Figure 9: Probability of success in the hematologic pipeline
37 Figure 10: Clinical trials in myelofibrosis
37 Figure 11: Top 10 drugs for clinical trials in myelofibrosis
38 Figure 12: Top 10 companies for clinical trials in myelofibrosis
38 Figure 13: Trial locations in myelofibrosis
39 Figure 14: Myelofibrosis trials status
40 Figure 15: Myelofibrosis trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of myelofibrosis, 2019–28
15 Table 2: Marketed drugs for myelofibrosis
18 Table 3: Pipeline drugs for myelofibrosis in the US
23 Table 4: Bomedemstat for Myelofibrosis (December 5, 2020)
24 Table 5: Momelotinib for Myelofibrosis (December 5, 2020)
25 Table 6: Pelabresib for Myelofibrosis (December 5, 2020)
26 Table 7: Momelotinib for Myelofibrosis (May 6, 2020)
28 Table 8: Navitoclax for Myelofibrosis (December 9, 2019)
29 Table 9: Reblozyl for Myelofibrosis (November 6, 2019)
30 Table 10: Pracinostat for Myelofibrosis (July 31, 2019)
36 Table 11: Historical global sales, by drug ($m), 2015–19
36 Table 12: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Coronary Artery Disease 
Sign up to the